INTRODUCTION
============

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides encroaching small vessels, from capillaries to intraparenchymal arterioles and venules. AAV consists of three variants, such as microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA).[@B1][@B2] Because AAV may induce damage to major organs, AAV can occasionally be fatal: One year-cumulative patient survival rates were reported to range from 82% to 95% in Western countries[@B3] and up to 79.1% in Japan.[@B4] Meanwhile, it was recently reported that 10-year cumulative patient survival rate was 92.8% in Korean patients with AAV.[@B5]

So far, C-reactive protein (CRP)/serum albumin ratio (CAR) has been introduced as an independent predictor of all-cause mortality in cancers, inflammatory diseases and septic conditions.[@B6][@B7][@B8] Since, AAV is also an inflammatory disease involving systemic major organs beyond vessels,[@B1][@B2] one could reasonably speculate that CAR might be a predictor of all-cause mortality during follow-up. However, no study has sought to clarify the clinical significance of CAR in predicting all-cause mortality in AAV patients. Hence, in this study, we investigated whether CAR could be an independent predictor of all-cause mortality in 170 patients with AAV.

MATERIALS AND METHODS
=====================

Patients
--------

We retrospectively reviewed the medical records of 170 patients with AAV based on the following inclusion criteria: 1) patients who were first classified as AAV from October 2000 to September 2017 at the Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital; 2) patients who fulfilled the American College of Rheumatology 1990 criteria for the classification of GPA and EGPA and then reclassified by the algorithm suggested by the European Medicines Agency in 2007, in which the authors added the modified contents of the Chapel Hill Consensus Conferences Nomenclature of Vasculitis proposed in 2012;[@B1][@B2] 3) patients who had well-documented medical records with which to assess both clinical manifestations at diagnosis and death during follow-up and to calculate vasculitis activity score represented by Birmingham vasculitis activity score (BVAS) and prognostic factors identified by five factor score (FFS, 2009) at diagnosis;[@B9][@B10] and 4) patients who had results on perinuclear (P)-ANCA and cytoplasmic (C)-ANCA or myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-ANCA levels at diagnosis. This study was approved by the Institutional Review Board of Severance Hospital (4-2017-0673) who waved the need for the patient written informed consent, as this was a retrospective study.

Clinical and laboratory data
----------------------------

We obtained age at diagnosis and gender as demographic data. We collected clinical and laboratory results at diagnosis as described in [Table 1](#T1){ref-type="table"}. Comorbidities belonging to BVAS or FFS (2009), such as diffuse alveolar haemorrhage and cardiovascular diseases, were excluded in risk factors. We also reviewed medications administered during follow-up. We defined the follow-up duration as the period from diagnosis to the last visit in surviving patients, while we defined it as the period from diagnosis to death in deceased patients. CAR was calculated as CRP (mg/L) divided by serum albumin (g/dL).

Statistical analyses
--------------------

All statistical analyses were conducted using SPSS software (version 23 for windows; IBM Corp., Armonk, NY, USA). The multivariable Cox hazards model was conducted to appropriately obtain hazard ratios (HR). In the multivariable Cox hazards model, the levels of protein, serum albumin, and CRP were excluded, because they are variables related to the equation for CAR. The optimal cut-off of CAR for death (10.35) was extrapolated by calculating the area under the receiver operator characteristic curve (sensitivity 64.3% and specificity 67.9%). Comparison of cumulative patient survivals between the two groups were analysed by the Kaplan-Meier survival analysis. *p*-values less than 0.05 were considered statistically significant.

RESULTS
=======

Baseline characteristics of 170 patients with AAV
-------------------------------------------------

The baseline characteristics are described in [Table 1](#T1){ref-type="table"}. The mean age was 55.0 years and 53 patients (31.2%) were male. The mean BVAS and FFS (2009) at diagnosis were 12.8 and 1.2, respectively. The initial mean CRP and serum albumin levels were 41.1 (mg/L) and 3.6 (g/dL), respectively, and the mean CAR at diagnosis was 14.8. Fourteen patients (8.2%) died during the mean follow-up of 56.7 months.

CAR at diagnosis and all-cause mortality during the follow-up
-------------------------------------------------------------

In univariable Cox hazard model analysis, CAR at diagnosis was significantly associated with all-cause mortality in AAV patients \[HR 1.037, 95% confidence interval (CI) 1.015--1.060\], along with age, BVAS, FFS (2009) ≥2, haemoglobin, blood urea nitrogen, alkaline phosphatase, total bilirubin, erythrocyte sedimentation rate, chronic kidney disease (CKD) ≥stage 3 and DM at diagnosis. However, medications showed no predictive value for mortality ([Table 2](#T2){ref-type="table"}).

Since BVAS and FFS (2009) share some items, we separately performed multivariable analysis with either BVAS or FFS (2009) ≥2, along with other variables with significance in univariable analysis. In multivariable Cox hazards model analysis with BVAS, CAR (HR 1.048) and DM (HR 6.313) were independent predictors of all-cause mortality in AAV patients ([Table 2](#T2){ref-type="table"}). Meanwhile, in multivariable Cox hazards model analysis with FFS (2009) ≥2, only CAR (HR 1.039) was an independent predictor of all-cause death in AAV patients ([Table 2](#T2){ref-type="table"}).

Optimal cut-off of CAR to predict all-cause mortality
-----------------------------------------------------

Cumulative patient survival rates according to CAR ≥10.35 and the presence of DM are depicted in [Fig. 1](#F1){ref-type="fig"}. In Kaplan-Meier survival analysis, patients with CAR ≥10.35 exhibited a higher frequency of all-cause mortality than those without (*p*\<0.001). Also, patients with DM also exhibited lower cumulative patient survival rate that those without (*p*=0.012).

DISCUSSION
==========

In this study, we investigated whether CAR at diagnosis could predict all-cause mortality during the follow-up of AAV. Also, we demonstrated that CAR at diagnosis is an independent predictor of all-cause mortality comparable to DM, the conventional risk factor of mortality. Also we provided an optimal cut-off of CAR at diagnosis to estimate the risk of all-cause mortality.

How CAR at diagnosis could be an independent predictor of all-cause death in AAV patients could be explained as follows: CRP is closely correlated with interleukin (IL)-6. Chronic inflammation enhances the production of IL-6, which, in turn, promotes the production of CRP in the liver, leading to an increase in CRP level in the peripheral circulation.[@B11] Meanwhile, IL-6 down-regulates or inhibits the production of albumin in the liver, resulting in a decrease in serum albumin concentration.[@B12] Accordingly, inflammatory burden can affect CAR via two different directions (increasing CRP and decreasing serum albumin), unlike CRP or serum albumin alone. Thus, CAR with two variables affected by inflammatory burden in AAV could be a more stable and reliable index to presuppose all-cause mortality, compared to CRP or serum albumin alone in AAV patients.

Here we provide two hypotheses regarding the connection between the inflammatory burdens at diagnosis and all-cause mortality in AAV patients. First, a large inflammatory burdens at diagnosis may provoke immunosuppressive drug-refractoriness or cause a situation where patients should take larger doses of immunosuppressive drugs or have a longer period to receive them. This situation may exacerbate the risk of infection and cancer development.[@B13] Second, a large inflammatory burden may reflect ready-made organ-damage at diagnosis and, furthermore, may result in end stage damage to various major organs during follow-up, such as diffuse alveolar haemorrhage and end stage renal disease.[@B9] This situation may aggravate the systemic complications of organ-damages by AAV, leading to an increase in all-cause mortality. In this study, the most common cause of death was serious infection in 12 patients \[pneumonia (n=7), bacterial sepsis (n=3), influenza infection (n=1), and biliary infection (n=1)\]. Two patients died of AAV-related complication \[diffuse alveolar haemorrhage (n=1) and cardiac arrest due to cardiomyopathy (n=1)\]. This result might support to our hypotheses.

In patients with AAV, infection, cardiovascular damage, malignancies, CKD, high BVAS, low haemoglobin, and immunosuppressive drugs were reported to be associated with all-cause mortality.[@B14] Meanwhile, age, male gender, DM, and hypertension are also considered as traditional risk factors of all-cause mortality in the general population.[@B15] Recently, in Korean patients with AAV, it was reported that FFS (2009) at diagnosis ≥2 was associated with mortality.[@B5] Accordingly, we included initial BVAS and FFS (2009) at diagnosis ≥2 in multivariable Cox hazard model analysis along with both AAV-related and traditional risk factors of all-cause mortality. In univariable analysis, almost all the risk factors exhibited predictive potential for mortality, similar to a previous study.[@B14] However, in both multivariable Cox hazards model analyses with either initial BVAS or FFS (2009) at diagnosis ≥2, only CAR at diagnosis and DM were identified as an independent predictor of all-cause of mortality. Unlike the previous study investigating whether the initial clinical features and medications administered could predict all-cause mortality,[@B5] this study evaluated the clinical implications of CAR among clinical and laboratory variables, and so there might be a subtle difference in the results between the two studies.

Although no predictive value for all-cause mortality was witnessed in ANCA positivity (*p*=0.084) or hypertension (*p*=0.088) in the univariable Cox hazards model analysis in this study, ANCA positivity is one of AAV-related risk factors for serious outcomes,[@B16] and furthermore, hypertension is a well-known conventional risk factor for mortality in the general population.[@B15] Thus, to minimise the effect of two confounding factors, we included ANCA positivity and hypertension in the univariable Cox hazard model analysis. Regardless of ANCA positivity and hypertension, only CAR exhibited statistical significance among variables when applying either BVAS at diagnosis or FFS (2009) at diagnosis ≥2 in the model (HR 1.050, *p*=0.025, and HR 1.042, *p*=0.039) ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online).

Our study has an advantage in that we first proved the clinical significance of CAR at diagnosis in predicting all-cause of mortality and furthermore, provided an optimal cut-off of CAR at diagnosis to estimate the risk of all-cause mortality. However, this study also has several limitations. First, as this study was designed as a retrospective study, we could not strictly control for confounding factors, including undocumented histories of medications, nutritional status related the level of serum albumin, and comorbidities. Second, as this study was conducted in a single centre, the number of deceased patients was too small to perform sub-group analysis based on the causes of mortality. Third, we could not use the cut-off of CAR in the multivariate Cox hazard model analysis to presuppose allcause mortality due to the small statistical power. This study may be a pilot study to first investigate the clinical implication of CAR in AAV patients. We believe that future prospective and multi-centric studies will validate the clinical implications of our results, and they will provide a clear optimal cut-off of CAR to predict all-cause mortality in AAV patients for use in real clinical settings. In conclusion, CAR at diagnosis can be an independent predictor of all-cause mortality, comparable to DM, the conventional risk factor of mortality.
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SUPPLEMENTARY MATERIAL
======================

###### Supplementary Table 1

Univariable and Multivariable Cox Hazards Model Analyses of Variables for All-Cause Death, Including Confounding Factors of ANCA Positivity and Hypertension, in AAV Patients during Follow-Up (n=170)

![A predictor of all cause-mortality in ANCA-associated vasculitis patients. Patients with CAR ≥10.35 and having DM exhibited a higher frequency of all-cause mortality than those without in Kaplan-Meier survival analysis. ANCA, antineutrophil cytoplasmic antibody; CAR, C-reactive protein to serum albumin ratio; DM, diabetes mellitus.](ymj-59-865-g001){#F1}

###### Baseline Characteristics of Patients with AAV (n=170)

![](ymj-59-865-i001)

  Variables                                                           Values
  ------------------------------------------------------------------- ---------------
  At diagnosis                                                        
   Demographic data                                                   
    Age at diagnosis (yr)                                             55.0±15.4
    Male gender                                                       53 (31.2)
   AAV variants                                                       
    MPA                                                               88 (51.8)
    GPA                                                               43 (25.3)
    EGPA                                                              39 (22.9)
   ANCA positivity                                                    129 (75.9)
    MPO-ANCA (or P-ANCA)                                              105 (61.8)
    PR3-ANCA (or C-ANCA)                                              28 (16.5)
    Both ANCAs                                                        8 (4.7)
    ANCA negative                                                     41 (24.1)
   Clinical manifestations                                            
    General                                                           75 (44.1)
    Cutaneous                                                         40 (23.5)
    Mucous membranes/eyes                                             12 (7.1)
    Ear Nose Throat                                                   64 (37.6)
    Pulmonary                                                         92 (54.1)
    Cardiovascular                                                    46 (27.1)
    Abdominal                                                         10 (5.9)
    Renal                                                             99 (58.2)
    Nervous systems                                                   54 (31.8)
   Activity and prognostic factor                                     
    BVAS                                                              12.8±7.0
    FFS (2009)                                                        1.2±1.0
   Laboratory results                                                 
    White blood cell (/mm^3^)                                         9992.8±4678.5
    Haemoglobin (g/dL)                                                11.5±2.3
    Platelet×10^3^ (/mm^3^)                                           324.5±139.0
    Blood urea nitrogen (mg/dL)                                       25.1±23.2
    Creatinine (mg/dL)                                                1.8±2.0
    Protein (g/dL)                                                    6.7±0.9
    Serum albumin (g/dL)                                              3.6±0.8
    Alkaline phosphatase (IU/L)                                       89.6±84.3
    Aspartate aminotransferase (IU/L)                                 24.0±24.4
    Alanine aminotransferase (IU/L)                                   23.5±35.3
    Total bilirubin                                                   0.7±1.4
   Acute reactants                                                    
    Erythrocyte sedimentation rate (mm/hr)                            59.0±37.3
    C-reactive protein (mg/L)                                         41.1±55.4
   CAR                                                                14.8±22.5
   Comorbidities except items of BVAS or FFS(2009) at diagnosis^\*^   
    Chronic kidney disease≥stage 3                                    44 (25.9)
    End stage renal disease                                           28 (16.5)
    Diabetes mellitus                                                 34 (20.0)
    Hypertension                                                      72 (42.4)
    Viral hepatitis                                                   6 (3.5)
  During follow-up                                                    
   Follow-up duration (months)                                        56.7±54.4
   Death                                                              14 (8.2)
   Medications administered                                           
    Glucocorticoid                                                    145 (85.8)
    Cyclophosphamide                                                  71 (42.0)
    Mycophenolate mofetil                                             10 (5.9)
    Azathioprine                                                      46 (27.2)
    Tacrolimus                                                        10 (5.9)
    Rituximab                                                         15 (8.9)
    Methotrexate                                                      13 (7.7)

AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham vasculitis activity score; FFS, five factor score; CAR, C-reactive protein to serum albumin ratio.

Values are expressed as a mean±standard deviation or number (%).

^\*^Interstitial lung disease, diffuse alveolar haemorrhage, ischemic heart diseases-related diseases and cerebrovascular accident are not included.

###### Univariable and Multivariable Cox Hazard Model Analyses of Variables for All-Cause Death in AAV Patients during the Follow-Up (n=170)

![](ymj-59-865-i002)

  Variables at diagnosis                                             Univariable analysis   Multivariable analysis (including BVAS at diagnosis)   Multivariable analysis \[including FFS (2009) at diagnosis\]                                                           
  ------------------------------------------------------------------ ---------------------- ------------------------------------------------------ -------------------------------------------------------------- ------- --------------- ------- ------- --------------- -------
  Demographic data at diagnosis                                                                                                                                                                                                                                           
   Age                                                               1.052                  1.009--1.097                                           0.017                                                          1.045   0.986--1.109    0.137   1.033   0.973--1.096    0.285
   Male gender                                                       1.265                  0.409--3.914                                           0.683                                                                                                                  
  ANCA positivity at diagnosis                                       3.779                  0.838--17.037                                          0.084                                                                                                                  
  Activity and prognostic factor                                                                                                                                                                                                                                          
   BVAS                                                              1.092                  1.014--1.177                                           0.021                                                          0.996   0.868--1.144    0.959   N/A     N/A             N/A
   FFS (2009)≥2                                                      10.101                 2.242--45.517                                          0.003                                                          N/A     N/A             N/A     6.175   0.632--60.319   0.117
  Laboratory results at diagnosis                                                                                                                                                                                                                                         
   White blood cell                                                  1.000                  1.000--1.000                                           0.743                                                                                                                  
   Haemoglobin                                                       0.651                  0.480--0.884                                           0.006                                                          0.763   0.477--1.219    0.258   0.864   0.523--1.426    0.566
   Platelet                                                          1.000                  0.995--1.004                                           0.944                                                                                                                  
   Blood urea nitrogen                                               1.014                  1.002--1.026                                           0.020                                                          1.018   0.992--1.046    0.176   1.012   0.989--1.036    0.295
   Creatinine                                                        1.098                  0.929--1.298                                           0.274                                                                                                                  
   Protein^\*^                                                       0.398                  0.192--0.823                                           0.013                                                          N/A     N/A             N/A     N/A     N/A             N/A
   Serum albumin^\*^                                                 0.138                  0.046--0.414                                           \<0.001                                                        N/A     N/A             N/A     N/A     N/A             N/A
   Alkaline phosphatase                                              1.004                  1.001--1.007                                           0.022                                                          1.000   0.991--1.008    0.950   1.001   0.994--1.008    0.826
   Aspartate aminotransferase (IU/L)                                 1.008                  0.998--1.018                                           0.124                                                                                                                  
   Alanine aminotransferase (IU/L)                                   1.006                  0.998--1.013                                           0.168                                                                                                                  
   Total bilirubin                                                   1.152                  1.022--1.298                                           0.021                                                          1.135   0.787--1.639    0.498   1.080   0.785--1.485    0.638
  Acute phase reactants at diagnosis                                                                                                                                                                                                                                      
   Erythrocyte sedimentation rate (mm/hr)                            1.018                  1.001--1.035                                           0.032                                                          1.004   0.976--1.033    0.782   1.011   0.980--1.042    0.499
   C-reactive protein (mg/L)^\*^                                     1.014                  1.004--1.023                                           0.006                                                          N/A     N/A             N/A     N/A     N/A             N/A
  CAR at diagnosis                                                   1.037                  1.015--1.060                                           0.001                                                          1.048   1.009--1.089    0.016   1.039   1.003--1.077    0.036
  Comorbidities except items of BVAS or FFS (2009) at diagnosis^†^                                                                                                                                                                                                        
   Chronic kidney disease≥stage 3                                    3.883                  1.253--12.031                                          0.019                                                          4.236   0.750--23.930   0.102   3.419   0.570--20.517   0.179
   End stage renal disease                                           1.140                  0.346--3.757                                           0.829                                                                                                                  
   Diabetes mellitus                                                 3.939                  1.239--12.526                                          0.020                                                          6.313   1.120--35.571   0.037   4.024   0.817--19.813   0.087
   Hypertension                                                      2.834                  0.856--9.386                                           0.088                                                                                                                  
   Viral hepatitis                                                   2.209                  0.275--17.759                                          0.456                                                                                                                  
  Medications administered during follow-up                                                                                                                                                                                                                               
   Glucocorticoid                                                    0.865                  0.191--3.927                                           0.851                                                                                                                  
   Cyclophosphamide                                                  1.895                  0.652--5.504                                           0.240                                                                                                                  
   Mycophenolate mofetil                                             1.871                  0.404--8.664                                           0.423                                                                                                                  
   Azathioprine                                                      0.136                  0.027--1.628                                           0.136                                                                                                                  
   Tacrolimus                                                        0.028                  0.000--18.759                                          0.282                                                                                                                  
   Rituximab                                                         1.554                  0.419--5.761                                           0.509                                                                                                                  
   Methotrexate                                                      0.029                  0.000--10.735                                          0.241                                                                                                                  

AAV, ANCA-associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis activity score; FFS, five factor score; CAR, C-reactive protein to serum albumin ratio; HR, hazard ratio; CI, confidence interval.

^\*^Protein, serum albumin and CRP were excluded in multivariable Cox hazard model analysis, because they are variables related to the equation for CAR. ^†^Interstitial lung disease, diffuse alveolar haemorrhage, ischemic heart diseases-related diseases, and cerebrovascular accident-related diseases were excluded as comorbidities.
